TrialHuman vaccines & immunotherapeutics2022

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.

Charu Sabharwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.